Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $6.1400 (6.04%) ($6.1400 - $6.1400) on Thu. Mar. 25, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.02% (three month average) | RSI | 52 | Latest Price | $6.1400(6.04%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -2% a day on average for past five trading days. | Weekly Trend | AUTL advances 0.2% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) BNDX(11%) SKYY(9%) TLT(9%) BND(8%) LIT(8%) | Factors Impacting AUTL price | AUTL will decline at least -2.01% in a week (0% probabilities). TBT(-9%) USO(-7%) UNG(-7%) XLF(-5%) XLB(-3%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.01% (StdDev 4.02%) | Hourly BBV | -0.1 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | Resistance Level | $6.5 | 5 Day Moving Average | $6.39(-3.91%) | 10 Day Moving Average | $6.56(-6.4%) | 20 Day Moving Average | $6.5(-5.54%) | To recent high | -34.6% | To recent low | 6% | Market Cap | $321m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |